UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 424

Sortiert nach

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

Annals of oncology, 2006-09, Vol.17 (9), p.1441-1449

2006

Link zum Volltext

Verfügbarkeit prüfen

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Annals of oncology, 2015-05, Vol.26 (5), p.921-927

2015

Link zum Volltext

Verfügbarkeit prüfen

P114 Characteristics of residual tumor after neoadjuvant chemotherapy (nact)may predict outcomes in patients with triple negative breast cancer (tnbc)

Breast (Edinburgh), 2023-04, Vol.68, p.S58-S58

2023

Link zum Volltext

Verfügbarkeit prüfen

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of oncology, 2024-02, Vol.35 (2), p.159-182

2024

Link zum Volltext

Verfügbarkeit prüfen

Role of FGFR2 amplification in prognosis of patients with ovarian cancer

Annals of oncology, 2018-10, Vol.29, p.viii354-viii355

2018

Link zum Volltext

Verfügbarkeit prüfen

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

Annals of oncology, 2015-01, Vol.26 (1), p.132-140

2015

Link zum Volltext

Verfügbarkeit prüfen

Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis

Annals of oncology, 2019-07, Vol.30, p.iv16-iv16

2019

Link zum Volltext

Verfügbarkeit prüfen

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Annals of oncology, 2011-01, Vol.22 (1), p.39-48

2011

Link zum Volltext

Verfügbarkeit prüfen

P-049A population study of correlation between the treatment rate for monoclonal antibodies (Mabs) and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii15-ii15

2016

Link zum Volltext

Verfügbarkeit prüfen

Dynamics of the monoclonal antibodies (MABs) treatment rate and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia from 2013 to 2016

Annals of oncology, 2018-06, Vol.29, p.v76-v76

2018

Link zum Volltext

Verfügbarkeit prüfen

Sequencing of KRAS and NRAS in 1501 colorectal carcinomas reveals significant share of mutations, which are not included in common diagnostic kits

Annals of oncology, 2018-10, Vol.29, p.viii195-viii195

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors of chemo-radiotherapy efficacy in patients with locally-advanced rectal cancer

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii169

2018

Link zum Volltext

Verfügbarkeit prüfen

Final results of the concordance analysis of PD-L1 immunohistochemistry (IHC) assays and polymerase chain reaction (PCR) in non-small lung cancer (NSCLC) patients

Annals of oncology, 2018-10, Vol.29, p.viii507-viii507

2018

Link zum Volltext

Verfügbarkeit prüfen

Association between duration of oxaliplatin-free interval and effect of reintroduction of oxaliplatin-containing chemotherapy in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2018-06, Vol.29, p.v76-v76

2018

Link zum Volltext

Verfügbarkeit prüfen

A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy

Annals of oncology, 2010-09, Vol.21 (9), p.1779-1785

2010

Link zum Volltext

Verfügbarkeit prüfen

2611 Treatment efficacy and prognostic factors in patients (pts) with metastatic nongerm cell tumors of testis

European journal of cancer (1990), 2015-09, Vol.51, p.S515-S515

2015

Link zum Volltext

Verfügbarkeit prüfen

2707 Quantitative immunofluorescent detection of RRM1 protein in ovarian cancer tissue by flow cytometry

European journal of cancer (1990), 2015-09, Vol.51, p.S534-S534

2015

Link zum Volltext

Verfügbarkeit prüfen

Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial

Annals of oncology, 2018-10, Vol.29, p.viii340-viii341

2018

Link zum Volltext

Verfügbarkeit prüfen

New data on molecular phenotype of ascitic tumor cells in ovarian cancer patients

European journal of cancer (1990), 2016-07, Vol.61, p.S75-S75

2016

Link zum Volltext

Verfügbarkeit prüfen

Digoxin is a modifier increasing platinum drug anticancer activity

European journal of cancer (1990), 2016-07, Vol.61, p.S136-S137

2016

Link zum Volltext

Verfügbarkeit prüfen

Quantitative analysis of estrogen receptors alpha and beta expression in ovarian cancer patients by flow cytometry

European journal of cancer (1990), 2016-07, Vol.61, p.S71-S71

2016

Link zum Volltext

Verfügbarkeit prüfen

Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung

Current medical research and opinion, 2015-06, Vol.31 (6), p.1117-1127

2015

Link zum Volltext

Verfügbarkeit prüfen

580_PR: Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience

Journal of thoracic oncology, 2016-04, Vol.11 (4 Suppl), p.S151

2016

Link zum Volltext

Verfügbarkeit prüfen

476 FGFR2 targeting with allosteric inhibitor RPT835

European journal of cancer (1990), 2014-11, Vol.50, p.155-155

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

European journal of cancer (1990), 2017-02, Vol.72, p.S96-S96

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 424

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(416)
Mit Volltextzugriff
(413)

Publikationsform

Sprache

Englisch
(414)
Russisch
(35)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(121)
Life Sciences & Biomedicine
(119)
Humans
(104)
Oncology
(102)
Female
(70)
Middle Aged
(62)
Adult
(61)
Aged
(53)
Male
(53)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(46)
Hematology, Oncology And Palliative Medicine
(43)
Treatment Outcome
(38)
Chemotherapy
(31)
Disease-Free Survival
(29)
Prognosis
(26)
Breast Neoplasms - Drug Therapy
(24)
Aged, 80 And Over
(22)
Cisplatin - Administration & Dosage
(19)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(18)
Breast Neoplasms - Pathology
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

P114 Characteristics of residual tumor after neoadjuvant chemotherapy (nact)may predict outcomes in patients with triple negative breast cancer (tnbc)

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Role of FGFR2 amplification in prognosis of patients with ovarian cancer

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

P-049A population study of correlation between the treatment rate for monoclonal antibodies (Mabs) and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia

Dynamics of the monoclonal antibodies (MABs) treatment rate and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia from 2013 to 2016

Sequencing of KRAS and NRAS in 1501 colorectal carcinomas reveals significant share of mutations, which are not included in common diagnostic kits

Prognostic factors of chemo-radiotherapy efficacy in patients with locally-advanced rectal cancer

Final results of the concordance analysis of PD-L1 immunohistochemistry (IHC) assays and polymerase chain reaction (PCR) in non-small lung cancer (NSCLC) patients

Association between duration of oxaliplatin-free interval and effect of reintroduction of oxaliplatin-containing chemotherapy in patients with metastatic colorectal cancer (mCRC)

A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy

2611 Treatment efficacy and prognostic factors in patients (pts) with metastatic nongerm cell tumors of testis

2707 Quantitative immunofluorescent detection of RRM1 protein in ovarian cancer tissue by flow cytometry

Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial

New data on molecular phenotype of ascitic tumor cells in ovarian cancer patients

Digoxin is a modifier increasing platinum drug anticancer activity

Quantitative analysis of estrogen receptors alpha and beta expression in ovarian cancer patients by flow cytometry

Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung

580_PR: Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience

476 FGFR2 targeting with allosteric inhibitor RPT835

Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

Suchergebnisse filtern